Vir Biotechnology reported an 88% cure rate for hepatitis D virus (HDV) in its Phase 2 SOLSTICE trial, described by a key opinion leader as the best rate in 50 years of HDV treatment. The company completed enrolment in all three registrational ECLIPSE trials, with top-line data from ECLIPSE 1 expected in Q4 2026. Vir strengthened its balance sheet significantly, ending Q2 2026 with approximately $1.01 billion in cash after receiving $315 million from Astellas. This extends its cash runway into the second half of 2028. The company is advancing its oncology pipeline, with VIR-5500 enrolling patients in multiple expansion cohorts. Vir aims to initiate Phase 3 registrational trials as early as next year. The company faces management turnover, actively searching for a new CMO and CFO. R&D expenses increased significantly year-over-year.

Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes. Filing Impact Filing Sentiment Rhea-AI filing summary. Vir Biotechnology, Inc. reported governance updates and voting results from its 2026 Annual Meeting of Stockholders. Director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, citing a business conflict and no disagreement with the company. Robert More was appointed Audit Committee Chair and the Board size was reduced from eight to seven members. Stockholders elected three Class I directors to serve until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. 8-K event classification. 2 items: 5.02, 5.07 Key figures. Shares entitled to vote: 161,234,058 shares Board size after change: 7 directors Say-on-pay votes for: 108,453,963 votes +3 more Key terms. Audit Committee, Annual Meeting of Stockholders, advisory vote on executive compensation, independent registered public accounting firm, +1 more Find StockTitan more easily in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 05/28/2026 - 06:01 AM Faq. What board change did Vir Biotechnology (VIR) disclose in this 8-K? Vir Biotechnology announced that director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, due to a business conflict. The filing states her decision is not related to any disagreement with the company's operations, policies, or practices. Who will chair Vir Biotechnology's (VIR) Audit Committee after the change? The Board appointed Robert More, MBA as Chair of the Audit Committee effective upon Saira Ramasastry's departure on May 26, 2026. At the same time, the Board approved reducing its size from eight to seven members, reflecting this change in composition and committee leadership. How many Vir Biotechnology (VIR) shares were entitled to vote at the 2026 annual meeting? As of the March 31, 2026 record date, 161,234,058 shares of Vir Biotechnology common stock were outstanding and entitled to vote at the 2026 Annual Meeting of Stockholders. These shares formed the basis for quorum and voting calculations on director elections and other proposals. Did Vir Biotechnology (VIR) stockholders approve executive compensation in 2026? Stockholders approved, on an advisory basis, the compensation of Vir Biotechnology's named executive officers. The proposal received 108,453,963 votes for, 11,863,405 votes against, 1,372,563 abstentions, and 16,677,343 broker non-votes, indicating overall support for the company's executive pay program. Which directors were elected at Vir Biotechnology's (VIR) 2026 annual meeting? Stockholders elected three Class I directors: Robert More, Janet Napolitano, and Elliott Sigal. For example, Elliott Sigal received 115,030,681 votes for and 6,659,250 votes withheld, with 16,677,343 broker non-votes. Each will serve until the 2029 Annual Meeting and until a successor is duly elected. Which audit firm did Vir Biotechnology (VIR) stockholders ratify for 2026? Stockholders ratified Ernst & Young LLP as Vir Biotechnology's independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 137,048,756 votes for, 153,836 votes against, and 1,164,682 abstentions, with no broker non-votes reported for this proposal. Filing exhibits & attachments. 4 documents